SecBot SecBot
6-K ·Filed May 11, 2026

STVN

Stevanato Group S.p.A.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001193125-26-215900
Notable filing: 6-K
Actionable Insight • Neutral

The filing is routine with no immediate catalyst. Monitor the shareholder meeting outcome and any updates on internal control remediation. The small dividend yield (~0.3% at current price) is not a meaningful shareholder return event.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
STVN ▲ +9.96% at T+60d
NEUTRAL call +9.96% · α vs SPY +5.56% · entry $18.28 → $20.10
Entry = T+0 close
May 11, 2026
via day close
T+1d
-0.22%
call -0.22% · α -0.08%
$18.24
settled 6mo ago
T+5d
-2.68%
call -2.68% · α -2.60%
$17.79
settled 5mo ago
T+20d
-1.34%
call -1.34% · α -1.04%
$18.03
settled 5mo ago
T+60d
+9.96%
call +9.96% · α +5.56%
$20.10
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Stevanato Group filed a 6-K containing the explanatory report for its ordinary and extraordinary shareholders meeting on May 26, 2026. The agenda includes approval of FY2025 financial statements (consolidated net profit of €139.8 million), a proposed €0.054 per share dividend, re-appointment of PwC as auditor, and by-law amendments. The filing is routine and contains no material unexpected financial information.

Key Facts

  • Shareholders meeting set for May 26, 2026 to approve FY2025 financial statements
  • Consolidated net profit of €139.8 million (€13.5 million parent company net profit)
  • Proposed dividend of €0.054 per share (ex-date June 11, payment July 29)
  • Re-appointment of PricewaterhouseCoopers S.p.A. as auditor for 2026-2028
  • By-law amendments to allow outgoing board to submit director slate and adjust Audit Committee composition
  • Authorization to purchase up to 1% of shares and dispose of up to 1,000,000 treasury shares
  • Audit Committee report discloses material weaknesses in internal control over financial reporting with remediation in progress

Financial Impact

Dividend distribution of approximately €14.7 million (€0.054 per share on 272.6 million shares, excluding 29.8 million treasury shares). Buyback authorization up to 1% of share capital, which is minor relative to $5.5B market cap.

netProfitdividendPerShare

Risk Factors

  • Ongoing material weaknesses in internal controls could lead to future restatements or SEC enforcement
  • Low dividend yield may disappoint income-focused investors

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
76% bullish (17 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-215900
Document: d101111dex993.htm0001193125-26-215900
Document: d101111dex994.htm0001193125-26-215900
4 reports for STVN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for STVN — sortable, filterable
TypeNow
Aug 10, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$21.05 $20.24▼ −3.85%▼ −2.79%$19.75 (−6.18%)
Aug 6, 2026
11w ago
6-K
NEUTRAL ★ 5/10
$20.27 $20.51▲ +1.18%▲ +1.58%$19.75 (−2.57%)
Aug 4, 2026
11w ago
6-K
BULLISH ★ 5/10
$20.10 $20.73▲ +3.13%▲ +3.74%$19.75 (−1.74%)
May 11, 2026
24w ago
6-K
NEUTRAL ★ 3/10
$18.28 $18.03▼ −1.34%▼ −1.04%$19.75 (+8.04%)
Showing 4 of 4

US Market Status

Market Open — Closes in 4h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026